One year in review 2017: novelties in the treatment of rheumatoid arthritis

被引：6
作者：
Ferro, F. [1 ]
Elefante, E. [1 ]
Luciano, N. [1 ]
Talarico, R. [1 ]
Todoerti, M. [2 ]
机构：
[1] Univ Pisa, Dept Clin & Expt Med, Rheumatol Unit, Via Roma 67, I-56126 Pisa, Italy
[2] Univ Pavia, Dept Rheumatol, IRCCS S Matteo, Pavia, Italy
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2017年 / 35卷 / 05期
关键词：
rheumatoid arthritis; therapy; DMARDs; TNF-inhibitor; small molecules; new treatment; MODIFYING ANTIRHEUMATIC DRUGS; NECROSIS-FACTOR INHIBITORS; B-VIRUS REACTIVATION; LOW DISEASE-ACTIVITY; OPEN-LABEL; INADEQUATE RESPONSE; BACKGROUND METHOTREXATE; EULAR RECOMMENDATIONS; RECEIVING RITUXIMAB; CERTOLIZUMAB PEGOL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rheumatoid arthritis (RA) is a chronic disease characterised by inflammation of the synovial tissue in joints, which can lead to joint destruction. The primary goal of the treatment is to control pain and inflammation, reduce joint damage and disability, and maintain or improve physical function and quality of life. The present review is aimed at providing a critical analysis of the recent literature on the novelties in the treatment of RA, with a particular focus on the most relevant studies published over the last year.
引用
收藏
页码：721 / 734
页数：14
相关论文
共 101 条
  • [1] Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis
    Abushouk, Abdelrahman Ibrahim
    Ahmed, Hussien
    Ismail, Ammar
    Elmaraezy, Ahmed
    Badr, Ahmed Said
    Gadelkarim, Mohamed
    Elnenny, Mohammed
    [J]. RHEUMATOLOGY INTERNATIONAL, 2017, 37 (07) : 1053 - 1064
  • [2] Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis
    Akiyama, Mitsuhiro
    Kaneko, Yuko
    Kondo, Harumi
    Takeuchi, Tsutomu
    [J]. CLINICAL RHEUMATOLOGY, 2016, 35 (11) : 2829 - 2834
  • [3] Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
    Aletaha, Daniel
    Bingham, Clifton O., III
    Tanaka, Yoshiya
    Agarwal, Prasheen
    Kurrasch, Regina
    Tak, Paul P.
    Popik, Sharon
    [J]. LANCET, 2017, 389 (10075) : 1206 - 1217
  • [4] Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/Ila clinical trial
    Alvaro-Gracia, Jose M.
    Jover, Juan A.
    Garcia-Vicuna, Rosario
    Carreno, Luis
    Alonso, Alberto
    Marsal, Sara
    Blanco, Francisco
    Martinez-Taboada, Victor M.
    Taylor, Peter
    Martin-Martin, Cristina
    DelaRosa, Olga
    Tagarro, Ignacio
    Diaz-Gonzalez, Federico
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 196 - 202
  • [5] Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both?
    Ansboro, Sharon
    Roelofs, Anke J.
    De Bari, Cosimo
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2017, 29 (02) : 201 - 207
  • [6] Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
    Atsumi, Tatsuya
    Tanaka, Yoshiya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Eguchi, Katsumi
    Watanabe, Akira
    Origasa, Hideki
    Yasuda, Shinsuke
    Yamanishi, Yuji
    Kita, Yasuhiko
    Matsubara, Tsukasa
    Iwamoto, Masahiro
    Shoji, Toshiharu
    Togo, Osamu
    Okada, Toshiyuki
    van der Heijde, Desiree
    Miyasaka, Nobuyuki
    Koike, Takao
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1348 - 1356
  • [7] Calabrò A, 2016, CLIN EXP RHEUMATOL, V34, P357
  • [8] Cantini F, 2017, SEMIN ARTHRITIS RHEU
  • [9] Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis
    Cantini, Fabrizio
    Niccoli, Laura
    Nannini, Carlotta
    Cassara, Emanuele
    Kaloudi, Olga
    Favalli, Ennio Giulio
    Becciolini, Andrea
    Biggioggero, Martina
    Benucci, Maurizio
    Li Gobbi, Francesca
    Grossi, Valentina
    Infantino, Maria
    Meacci, Francesca
    Manfredi, Mariangela
    Guiducci, Serena
    Bellando-Randone, Silvia
    Matucci-Cerinic, Marco
    Foti, Rosario
    Di Gangi, Marcella
    Mosca, Marta
    Tani, Chiara
    Palmieri, Fabrizio
    Goletti, Delia
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 45 (05) : 519 - 532
  • [10] Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO
12345678910